These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 17668553)

  • 1. Plasma concentrations of the HIV-protease inhibitor lopinavir are suboptimal in children aged 2 years and below.
    Verweel G; Burger DM; Sheehan NL; Bergshoeff AS; Warris A; van der Knaap LC; Driessen G; de Groot R; Hartwig NG
    Antivir Ther; 2007; 12(4):453-8. PubMed ID: 17668553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of a once-daily regimen of lopinavir/ritonavir in HIV-1-infected children.
    van der Lee M; Verweel G; de Groot R; Burger D
    Antivir Ther; 2006; 11(4):439-45. PubMed ID: 16856617
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and tolerability of once- versus twice-daily lopinavir/ritonavir treatment in HIV-1-infected children.
    la Porte C; van Heeswijk R; Mitchell CD; Zhang G; Parker J; Rongkavilit C
    Antivir Ther; 2009; 14(4):603-6. PubMed ID: 19578247
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Double boosted protease inhibitors, saquinavir, and lopinavir/ritonavir, in nucleoside pretreated children at 48 weeks.
    Kosalaraksa P; Bunupuradah T; Engchanil C; Boonrak P; Intasan J; Lumbiganon P; Burger D; Ruxrungtham K; Schutz M; Ananworanich J;
    Pediatr Infect Dis J; 2008 Jul; 27(7):623-8. PubMed ID: 18520443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and 48 week efficacy of low-dose lopinavir/ritonavir in HIV-infected children.
    Puthanakit T; van der Lugt J; Bunupuradah T; Ananworanich J; Gorowara M; Phasomsap C; Jupimai T; Boonrak P; Pancharoen C; Burger D; Ruxrungtham K
    J Antimicrob Chemother; 2009 Nov; 64(5):1080-6. PubMed ID: 19729375
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety, efficacy and development of resistance under the new protease inhibitor lopinavir/ritonavir: 48-week results.
    Voigt E; Wasmuth JC; Vogel M; Mauss S; Schmutz G; Kaiser R; Rockstroh JK
    Infection; 2004 Apr; 32(2):82-8. PubMed ID: 15057572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of drug resistance algorithms and genotypic inhibitory quotient in prediction of lopinavir-ritonavir treatment response in human immunodeficiency virus type 1 protease inhibitor-experienced patients.
    Maillard A; Chapplain JM; Tribut O; Bentué-Ferrer D; Tattevin P; Arvieux C; Michelet C; Ruffault A
    J Clin Virol; 2007 Feb; 38(2):131-8. PubMed ID: 17208042
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of lopinavir in HIV type-1-infected children taking the new tablet formulation once daily.
    van der Flier M; Verweel G; van der Knaap LC; van Jaarsveld P; Driessen GJ; van der Lee M; Hartwig NG; Burger DM
    Antivir Ther; 2008; 13(8):1087-90. PubMed ID: 19195335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of a double-boosted protease inhibitor combination, saquinavir and lopinavir/ritonavir, in pretreated children at 96 weeks.
    Bunupuradah T; van der Lugt J; Kosalaraksa P; Engchanil C; Boonrak P; Puthanakit T; Mengthaisong T; Mahanontharit A; Lumbiganon P; Tompkins E; Burger D; Ruxrungtham K; Ananworanich J;
    Antivir Ther; 2009; 14(2):241-8. PubMed ID: 19430099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amprenavir and lopinavir pharmacokinetics following coadministration of amprenavir or fosamprenavir with lopinavir/ritonavir, with or without efavirenz.
    Pham PA; Hendrix CW; Barditch-Crovo P; Parsons T; Khan W; Parish M; Radebaugh C; Carson KA; Pakes GE; Qaqish R; Flexner C
    Antivir Ther; 2007; 12(6):963-9. PubMed ID: 17926651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lopinavir/ritonavir exposure in treatment-naive HIV-infected children following twice or once daily administration.
    Rosso R; Di Biagio A; Dentone C; Gattinara GC; Martino AM; Viganò A; Merlo M; Giaquinto C; Rampon O; Bassetti M; Gatti G; Viscoli C
    J Antimicrob Chemother; 2006 Jun; 57(6):1168-71. PubMed ID: 16606636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected children.
    Sáez-Llorens X; Violari A; Deetz CO; Rode RA; Gomez P; Handelsman E; Pelton S; Ramilo O; Cahn P; Chadwick E; Allen U; Arpadi S; Castrejón MM; Heuser RS; Kempf DJ; Bertz RJ; Hsu AF; Bernstein B; Renz CL; Sun E
    Pediatr Infect Dis J; 2003 Mar; 22(3):216-24. PubMed ID: 12634581
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced lopinavir exposure during pregnancy.
    Stek AM; Mirochnick M; Capparelli E; Best BM; Hu C; Burchett SK; Elgie C; Holland DT; Smith E; Tuomala R; Cotter A; Read JS
    AIDS; 2006 Oct; 20(15):1931-9. PubMed ID: 16988514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ritonavir-boosted atazanavir-lopinavir combination: a pharmacokinetic interaction study of total, unbound plasma and cellular exposures.
    Colombo S; Buclin T; Franc C; Guignard N; Khonkarly M; Tarr PE; Rochat B; Biollaz J; Telenti A; Decosterd LA; Cavassini M
    Antivir Ther; 2006; 11(1):53-62. PubMed ID: 16518960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low dose lopinavir/ritonavir tablet achieves adequate pharmacokinetic parameters in HIV-infected Thai adolescents.
    Klinklom A; Puthanakit T; Gorowara M; Phasomsap C; Kerr S; Sriheara C; Ananworanich J; Burger D; Ruxrungtham K; Pancharoen C
    Antivir Ther; 2012; 17(2):283-9. PubMed ID: 22293065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The plasma and intracellular steady-state pharmacokinetics of lopinavir/ritonavir in HIV-1-infected patients.
    Crommentuyn KM; Mulder JW; Mairuhu AT; van Gorp EC; Meenhorst PL; Huitema AD; Beijnen JH
    Antivir Ther; 2004 Oct; 9(5):779-85. PubMed ID: 15535416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance.
    Molina JM; Ait-Khaled M; Rinaldi R; Penco G; Baril JG; Cauda R; Soriano V; Pialoux G; Wire MB; Lou Y; Givens N; Craig C; Nichols WG; Barbosa I; Yeo J;
    J Antimicrob Chemother; 2009 Aug; 64(2):398-410. PubMed ID: 19515730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atazanavir and lopinavir/ritonavir: pharmacokinetics, safety and efficacy of a promising double-boosted protease inhibitor regimen.
    Ribera E; Azuaje C; Lopez RM; Diaz M; Feijoo M; Pou L; Crespo M; Curran A; Ocaña I; Pahissa A
    AIDS; 2006 May; 20(8):1131-9. PubMed ID: 16691064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients.
    Benson CA; Deeks SG; Brun SC; Gulick RM; Eron JJ; Kessler HA; Murphy RL; Hicks C; King M; Wheeler D; Feinberg J; Stryker R; Sax PE; Riddler S; Thompson M; Real K; Hsu A; Kempf D; Japour AJ; Sun E
    J Infect Dis; 2002 Mar; 185(5):599-607. PubMed ID: 11865416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of early and confirmed virological response by genotypic inhibitory quotients for lopinavir in patients naïve for lopinavir with limited exposure to previous protease inhibitors.
    Torti C; Uccelli MC; Quiros-Roldan E; Gargiulo F; Tirelli V; Lapadula G; Regazzi M; Pierotti P; Tinelli C; De Luca A; Patroni A; Manca N; Carosi G
    J Clin Virol; 2006 Apr; 35(4):414-9. PubMed ID: 16280255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.